Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 4,986 matching trials from the live ClinicalTrials.gov search.

Filters: San Diego, California Clear all

Conditions: Obstructive Sleep Apnea
Interventions: Sleep Apnea Self-Management Program; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 70 Years
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: COVID-19 Infection, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Survey Administration; Procedure · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 6 Months to 37 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 72
States / cities: Birmingham, Alabama • Kingman, Arizona • Oakland, California + 50 more

Conditions: Migraine
Interventions: Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo; Drug
Lead sponsor: TriGemX Bio, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more

Conditions: Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Squamous Cell Lung Carcinoma, Stage IV Large Cell Lung Carcinoma, Stage IV Lung Adenocarcinoma, Stage IV Squamous Cell Lung Carcinoma
Interventions: Bevacizumab, Carboplatin, Cetuximab, Laboratory Biomarker Analysis, Paclitaxel; Biological · Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 1,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2022
U.S. locations: 797
States / cities: Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 473 more

Conditions: Treatment Resistant Depression (TRD)
Interventions: aiTBS; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 3
States / cities: San Diego, California • New York, New York • Dallas, Texas

Conditions: Prostate Cancer
Interventions: Stereotactic Radiosurgery using the Novalis Tx; Radiation
Lead sponsor: San Diego Radiosurgery; Industry
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Escondido, California

Conditions: Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer, Recurrent Thyroid Cancer
Interventions: dabrafenib, trametinib; Drug
Lead sponsor: Bhavana Konda; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 5
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 2 more

Conditions: Schizophenia Disorder, Schizoaffective Disorder
Interventions: Mobile Intervention for Social Recovery in Serious Mental Illness (mSITE), Supportive Contact (SC); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 65 Years
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Diego, California

Conditions: Inflammatory Bowel Disease
Interventions: Filgotinib, Placebo, Standard of Care; Drug
Lead sponsor: Lakefront Biotherapeutics NV; Industry
Eligibility: 21 Years to 65 Years · Male only
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: San Diego, California • Lakewood Rch, Florida • Miami, Florida + 7 more

Conditions: PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Interventions: RP-A601; Genetic
Lead sponsor: Rocket Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: La Jolla, California • Durham, North Carolina • Philadelphia, Pennsylvania

Conditions: Colorectal Neoplasms
Interventions: Eflornithine placebo & sulindac placebo, eflornithine & sulindac placebo, Eflornithine placebo & sulindac, Eflornithine plus sulindac; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 354 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2032
U.S. locations: 989
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more

Conditions: Diabetes Mellitus
Interventions: Glucose measurements; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Rhinosinusitis With Nasal Polyps
Interventions: Itepekimab (SAR440340), Placebo, Mometasone furoate nasal spray (MFNS); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • La Mesa, California • Los Angeles, California + 12 more

Conditions: Time Restricted Eating, Obstructive Sleep Apnea
Interventions: Time restricted eating; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 70 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Obesity
Interventions: CX11, Placebo; Drug · Other
Lead sponsor: Corxel Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 17
States / cities: Phoenix, Arizona • Inglewood, California • San Diego, California + 13 more

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Colitis
Interventions: Enhanced Digital Care, Education; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 13 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 9
States / cities: Scottsdale, Arizona • San Diego, California • San Francisco, California + 6 more

Conditions: Suicide Risk | Patient
Interventions: SAFE VET; Behavioral
Lead sponsor: VA Eastern Colorado Health Care System; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 8
States / cities: Long Beach, California • San Diego, California • Denver, Colorado + 5 more

Conditions: Metastatic BRCA Hereditary Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Cisplatin, Laboratory Biomarker Analysis, Placebo Administration, Veliparib; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 798
States / cities: Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 542 more

Conditions: Cytomegalovirus Retinitis, HIV Infections
Interventions: Fomivirsen sodium, Ganciclovir; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 18
States / cities: Los Angeles, California • Pasadena, California • San Diego, California + 14 more

Conditions: Hereditary Angioedema
Interventions: C1 esterase inhibitor [human] (C1INH-nf), Placebo (saline); Biological · Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 16
States / cities: Scottsdale, Arizona • San Diego, California • Walnut Creek, California + 13 more

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)
Interventions: SPD489; Drug
Lead sponsor: Shire; Industry
Eligibility: 4 Years to 5 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 50
States / cities: Dothan, Alabama • Little Rock, Arkansas • Imperial, California + 41 more

Conditions: Epilepsy, Generalized, Absence Epilepsy, Absence Seizures, Seizures, Seizure Disorder
Interventions: Eye movement analysis; Diagnostic Test
Lead sponsor: Rachel Kuperman; Industry
Eligibility: 4 Years to 100 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 5
States / cities: Orange, California • San Diego, California • San Francisco, California + 2 more

Conditions: HER2-negative Metastatic Breast Cancer
Interventions: DAN-222, Niraparib; Drug
Lead sponsor: Dantari, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 9
States / cities: La Jolla, California • Santa Monica, California • Tampa, Florida + 6 more

Conditions: Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease
Interventions: ProTmune, Control Arm; Biological
Lead sponsor: Fate Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 15
States / cities: Birmingham, Alabama • Duarte, California • San Diego, California + 12 more

Search by objective public record fields.

Self-Management of Continuous Positive Airway Pressure Settings

Evaluation of Immunologic Response Following COVID-19 Vaccination in Children, Adolescents, and Young Adults With Cancer

A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Neuronavigated aiTBS for TRD

Stereotactic Hypofractionated Radiosurgery for Early Stage Prostate Cancer

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

Context-Aware Mobile Intervention for Social Recovery in Serious Mental Illness (R33)

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease

A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

S0820, Adenoma and Second Primary Prevention Trial

Epidermal Adhesive Sensors to Enhance Continuous Glucose Measurement in Patients With Diabetes: The EASE Study

A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps

Time Restricted Eating in Sleep Apnea

A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants

Improving Outcomes and Reducing Disparities for Patients With Inflammatory Bowel Disease Through Epidemiology and Enhanced Disease Management

A Brief Intervention to Reduce Suicide Risk in Military Service Members and Veterans- Study 1

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )

C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks

Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder

Detecting Absence Seizures Using Eye Tracking

A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies